Deleted ICD-10-PCS Code XW04392 Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2

New Technology›Anatomical Regions›Introduction
  • Deleted — Not Valid for Claims
  • Valid FY 2020–2022
  • Deleted in FY 2023
CMS Source: CMS ICD-10-PCS code files FY 2020–2022 and the ICD-10-PCS conversion table.
Do not report XW04392 for inpatient discharges on or after October 1, 2022. Claims with a deleted code are rejected. Use one of the replacement codes below.

XW04392 is a deleted ICD-10-PCS code, removed from the code set effective October 1, 2022. It was valid for introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2 on inpatient discharges from October 1, 2019 through September 30, 2022, and later discharges must use a current code. The CMS conversion table maps it to 3E043GC.

Replacement Codes for XW04392

The CMS ICD-10-PCS conversion table maps XW04392 to this code. Confirm the choice against the procedure documentation and the code page's table.

  • 3E043GC Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach

Current Codes Starting With XW04

Active FY 2027 codes that share the first 4 characters of XW04392 (same table and body part).

  • XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0430B Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0431B Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW0433A Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW0434A Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0435A Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0436C Introduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12
  • XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
  • XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0439A Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
  • XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043CA Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
  • XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043FB Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043L6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043MA Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10

See the full XW0 table →

Code History

FY 2020AddedAdded to the ICD-10-PCS code setEffective October 1, 2019.
FY 2022Last fiscal year the code was validValid for discharges through September 30, 2022.
FY 2023DeletedRemoved from the ICD-10-PCS code setEffective October 1, 2022.

Questions About XW04392

Is XW04392 still a valid ICD-10-PCS code?

No. XW04392 was deleted from ICD-10-PCS effective October 1, 2022, with the FY 2023 code set. It cannot be reported for inpatient discharges on or after that date.

What replaced XW04392?

The CMS ICD-10-PCS conversion table maps XW04392 to 3E043GC. Confirm it matches the procedure documentation before you use it; a conversion is a starting point, not an automatic substitution.

Can I still use XW04392 for older discharges?

Yes, for inpatient discharges from October 1, 2019 through September 30, 2022. ICD-10-PCS codes are assigned by the code set in effect on the date of discharge, so a corrected or late claim for a discharge in that window still uses XW04392.